Literature DB >> 20011567

Accomplishments in 2008 in the management of advanced gastroesophageal cancer.

Salah-Eddin Al-Batran1, Jaffer A Ajani.   

Abstract

Overview of the Disease Process IncidencePrognosisPrognostic or Predictive FactorsCurrent General Therapy Standards Regional VariationsEvidence for Individual AgentsAccomplishments in 2008 TherapyBiomarkersBasic ScienceWhat Needs to be Done Applications of the AccomplishmentsControversies and DisagreementsSpecial PopulationsFuture Directions Comments on ResearchObstacles to Progress.

Entities:  

Year:  2009        PMID： 20011567      PMCID： PMC2791384     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  12 in total

1.  The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence.

Authors:  Heiko Pohl; H Gilbert Welch
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

2.  The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis.

Authors:  S A Hundahl; J L Phillips; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

Review 3.  Gastric cancer.

Authors:  Vincenzo Catalano; Roberto Labianca; Giordano D Beretta; Gemma Gatta; Filippo de Braud; Eric Van Cutsem
Journal:  Crit Rev Oncol Hematol       Date:  2005-06       Impact factor: 6.312

4.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

5.  Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival.

Authors:  Pooja R Rohatgi; James C Yao; Kenneth Hess; Isac Schnirer; Asif Rashid; Paul F Mansfield; Peter W Pisters; Jaffer A Ajani
Journal:  Cancer       Date:  2006-12-01       Impact factor: 6.860

6.  S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.

Authors:  Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi
Journal:  Lancet Oncol       Date:  2008-02-20       Impact factor: 41.316

7.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

8.  Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.

Authors:  Salah-Eddin Al-Batran; Joerg Thomas Hartmann; Stephan Probst; Harald Schmalenberg; Stephan Hollerbach; Ralf Hofheinz; Volker Rethwisch; Gernot Seipelt; Nils Homann; Gerhard Wilhelm; Gunter Schuch; Jan Stoehlmacher; Hans Günter Derigs; Susanna Hegewisch-Becker; Johannes Grossmann; Claudia Pauligk; Akin Atmaca; Carsten Bokemeyer; Alexander Knuth; Elke Jäger
Journal:  J Clin Oncol       Date:  2008-03-20       Impact factor: 44.544

9.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

10.  Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.

Authors:  M Dank; J Zaluski; C Barone; V Valvere; S Yalcin; C Peschel; M Wenczl; E Goker; L Cisar; K Wang; R Bugat
Journal:  Ann Oncol       Date:  2008-06-16       Impact factor: 32.976
View more
  1 in total

1.  Geographic difference in safety and efficacy of systemicchemotherapy for advanced gastric or gastroesophagealcarcinoma: a meta-analysis and meta-regression.

Authors:  Chiun Hsu; Ying-Chun Shen; Chia-Chi Cheng; Ann-Lii Cheng; Fu-Chang Hu; Kun-Huei Yeh
Journal:  Gastric Cancer       Date:  2012-05-12       Impact factor: 7.370
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.